Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy
American Journal of Nephrology · 19.05.2025 · 57 (1) · 21-29
DOI: 10.1159/000545995 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Nephrology, online erschienen am 19.05.2025. Verfasst von Huixian Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Rituximab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Rituximab has become the first-line therapy for patients with membranous nephropathy (MN). However, approximately 30–40% of patients with MN do not respond to rituximab. We presented our single-center experience of treating rituximab-refractory MN with obinutuzumab which is a humanized and glycoengineered type II anti-CD20 monoclonal antibody.
Methods
Seventeen patients with rituximab-refractory phospholipase A2 receptor (PLA2R)-associated MN who received obinutuzumab at the First Affiliated Hospital of Xi’an Jiaotong University were included in this case series study. Clinical and laboratory parameters were evaluated at presentation, before and after obinutuzumab administration.
Results
Of all patients with an average age of 49.7 ± 13.7 years, 11 (64.7%) patients were men. The median disease duration was 12 (12, 42) months. At presentation, the proteinuria and serum albumin levels were 7.51 ± 3.55 g/day and 22.1 ± 3.6 g/L, respectively. The mean estimated glomerular filtration rate level was 103.5 ± 12.9 mL/min/1.73 m2, and the patients had a baseline anti-PLA2R level of 183.2 ± 92.9 RU/mL. At obinutuzumab administration, proteinuria and albumin levels were still consistent with nephrotic syndrome. After a median follow-up of 12.6 ± 5.0 months, complete remission was achieved in 9 (52.9%) and partial remission was achieved in 6 (41.2%) cases. Of the patients who achieved remission, the median remission time was 4.4 (4.0, 6.0) months. At 6 months, 12 (70.6%) patients achieved remission and 11 of 12 patients with available PLA2R measurements reached immunological remission.
Conclusion
Obinutuzumab may represent an attractive alternative therapy in rituximab-refractory patients. Larger prospective studies are needed to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Human Anatomy, Histology and Embryology, Xi'an Jiaotong University Health Science Center, Xi'an, China.
- Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, luwanhong@xjtu.edu.cn.
Zitieren
APA
Li, H., Jin, L., Xie, X., Sun, J., Niu, D., Feng, J., Xu, G., Zhang, X., Khalaf, A. M. S., & Lu, W. (2025). Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy. American Journal of Nephrology, 57(1), 21-29. https://doi.org/10.1159/000545995
Vancouver
Li H, Jin L, Xie X, Sun J, Niu D, Feng J, et al. Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy. American Journal of Nephrology. 2025;57(1):21-29. doi:10.1159/000545995
BibTeX
@article{Li2025,
author = {Li, Huixian and Jin, Li and Xie, Xinfang and Sun, Jiping and Niu, Dan and Feng, Jie and Xu, Guiqing and Zhang, Xiaotian and Khalaf, Abdulrahman Majeed S and Lu, Wanhong},
title = {Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy},
journal = {American Journal of Nephrology},
year = {2025},
volume = {57},
number = {1},
pages = {21--29},
doi = {10.1159/000545995}
}
EUVIMED